Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats

Hepatology

Volumn 61, Issue 5, 2015, Pages 1672-1684

  Hsu, Shao Jung ^a,b   Lee, Fa Yauh ^a,b   Wang, Sun Sang ^a,b   Hsin, I Fang ^a,b   Lin, Te Yueh ^b   Huang, Hui Chun ^a,b   Chang, Ching Chih ^a,b   Chuang, Chiao Lin ^a,b   Ho, Hsin Ling ^b   Lin, Han Chieh ^a,b   Lee, Shou Dong ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHENG HSIN GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CYCLOPENTYLADENOSINE; CAFFEINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; THIOACETAMIDE; VASCULOTROPIN; VASCULOTROPIN C;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY BLOOD FLOW; ARTICLE; BILE DUCT LIGATION; COMMON BILE DUCT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENSITY; DOWN REGULATION; ENDOTHELIUM CELL; HEART INDEX; IN VITRO STUDY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PERFUSION; LIVER PROTECTION; LIVER SINUSOID; MESENTERIC VASCULAR DENSITY.; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; SPRAGUE DAWLEY RAT; STELLATE CELL; SUPERIOR MESENTERIC ARTERY; SUPERIOR MESENTERIC ARTERY FLOW; SYSTEMIC VASCULAR RESISTANCE; ANIMAL; COLLATERAL CIRCULATION; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, PORTAL; PORTAL VEIN;

ANIMALS; CAFFEINE; COLLATERAL CIRCULATION; HEMODYNAMICS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; PORTAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84928214684     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27679     Document Type: Article

References (51)

1. Bosch J, Pizcueta P, Feu F, Fernández M, Garciá-Pagán JC. Pathophysiology of portal hypertension. Gastroenterol Clin North Am 1992;21:1-14.
2. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009;49:1245-1256.
3. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-142.
4. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 2005;43:98-103.
5. Huang HC, Chu CJ, Lee FY, Chang FY, Wang SS, Lin HC, et al. Chronic inhibition of nitric oxide ameliorates splanchnic hyposensitivity to glypressin in a hemorrhage-transfused rat model of portal hypertension. Scand J Gastroenterol 2000;35:1308-1313.
6. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2005;128:24-32.
7. Modi AA, Feld JJ, Park Y, Kleiner DE, Everhart JE, Liang TJ, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010;51:201-209.
8. Larsson SC, Wolk A. Coffee consumption and risk of liver cancer: a meta-analysis. Gastroenterology 2007;132:1740-1745.
9. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012;56:1983-1992.
10. Echeverri D, Montes FR, Cabrera M, Galán A, Prieto A. Caffeine's vascular mechanisms of action. Int J Vasc Med 2010;2010:834060.
11. Zipprich A, Mehal WZ, Ripoll C, Groszmann RJ. A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatatory response in the CCl-cirrhotic liver. Liver Int 2010;30:988-994.
12. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Path 1984;65:305-311.
13. Zhang J, Luo B, Tang L, Wang Y, Stockard CR, Kadish I, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology 2009;136:1070-1080.
14. ω-nitro-L- arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464-1470.
15. Huang HC, Wang SS, Hsin IF, Chang CC, Lee FY, Lin HC, et al. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats. Hepatology 2012;56:248-258.
16. Albillos A, Colombato LA, Groszmann RJ. Vasodilatation and sodium retention in prehepatic portal hypertension. Gastroenterology 1992;102:931-935.
17. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol 1981;240:G371-G375.
18. Hodeige D, de Pauw M, Eechaute W, Weyne J, Heyndrickx GR. On the validity of blood flow measurement using colored microspheres. Am J Physiol 1999;276:H1150-H1158.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
20. Tsai MH, Iwakiri Y, Cadelina G, Sessa WC, Groszmann RJ. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003;125:1452-1461.
21. Hamilton RL, Berry MN, Williams MC, Severinghaus EM. A simple and inexpensive membrane "lung" for small organ perfusions. J Lipid Res 1974;15:182-186.
22. Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 1994;267:G416-G422.
23. Chan CC, Lee FY, Wang SS, Chang FY, Lin HC, Chu CJ, et al. Effects of vasopressin on portal-systemic collaterals in portal hypertensive rats: role of nitric oxide and prostaglandin. Hepatology 1999;30:630-635.
24. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of the endothelium. Am J Physiol 1992;263:G544-G550.
25. Braet F, De Zanger R, Sasaoki T, Baekeland M, Janssens P, Smedsrød B, et al. Assessment of a method of isolation, purification, and cultivation of rat liver sinusoidal endothelial cells. Lab Invest 1994;70:944-952.
26. Ho TC, Chen SL, Shih SC, Wu JY, Han WH, Cheng HC, et al. Pigment epithelium-derived factor is an intrinsic antifibrosis factor targeting hepatic stellate cells. Am J Pathol 2010;177:1798-1811.
27. Ramm GA. Isolation and culture of rat hepatic stellate cells. J Gastroenterol Hepatol 1998;13:846-851.
28. Xie G, Choi SS, Syn WK, Michelotti GA, Swiderska M, Karaca G, et al. Hedgehog signalling regulates liver sinusoidal endothelial cell capillarisation. Gut 2013;62:299-309.
29. Shim SG, Jun DW, Kim EK, Saeed WK, Lee KN, Lee HL, et al. Caffeine attenuates liver fibrosis via defective adhesion of hepatic stellate cells in cirrhotic model. J Gastroenterol Hepatol 2013;28:1877-1884.
30. Bienvenu T1, Pons G, Rey E, Richard MO, d'Athis P, Olive G. Effect of hypophysectomy on caffeine elimination in rats. Fundam Clin Pharmacol 1990;4:393-399.
31. Costenla AR, Cunha RA, de Mendonça A. Caffeine, adenosine receptors, and synaptic plasticity. J Alzheimers Dis 2010;20:S25-S34.
32. Gandhi KK, Williams JM, Menza M, Galazyn M, Benowitz NL. Higher serum caffeine in smokers with schizophrenia compared to smoking controls. Drug Alcohol Depend 2010;110:151-155.
33. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012;55:429-436.
34. Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, et al. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. Br J Pharmacol 2006;148:1144-1155.
35. Hsu SJ, Huang HC. Management of ascites in patients with liver cirrhosis: recent evidence and controversies. J Chin Med Assoc 2013;76:123-130.
36. Abraldes JG, Pasarín M, García-Pagán JC. Animal models of portal hypertension. World J Gastroenterol 2006;12:6577-6584.
37. Wang H, Guan W, Yang W, Wang Q, Zhao H, Yang F, et al. Caffeine inhibits the activation of hepatic stellate cells induced by acetaldehyde via adenosine A2A receptor mediated by the cAMP/PKA/SRC/ERK1/2/P38 MAPK signal pathway. PLoS One 2014;9:e92482.
38. Arauz J, Zarco N, Segovia J, Shibayama M, Tsutsumi V, Muriel P. Caffeine prevents experimental liver fibrosis by blocking the expression of TGF-β. Eur J Gastroenterol Hepatol 2014;26:164-173.
39. Li H, Jin SY, Son HJ, Seo JH, Jeong GB. Caffeine-induced endothelial cell death and the inhibition of angiogenesis. Anat Cell Biol 2013;46:57-67.
40. Newman PJ, Berndt MC, Gorski J, White GC, 2nd, Lyman S, Paddock C, et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990;247:1219-1222.
41. Muñoz-Chápuli R, Quesada AR, Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 2004;61:2224-2243.
42. Zhang R, Wang L, Zhang L, Chen J, Zhu Z, Zhang Z, et al. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circ Res 2003;92:308-313.
43. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, Zhang C, et al. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol 2007;62:49-58.
44. Mathew RJ, Wilson WH. Caffeine induced changes in cerebral circulation. Stroke 1985;16:814-817.
45. Kwan CY. Tetrandrine potentiates caffeine-induced contraction but inhibits phenylephrine-induced contraction in perfused rat mesenteric artery. Naunyn-Schmiedebergs Arch Pharmacol 2002;366:613-619.
46. Hatano Y, Mizumoto K, Yoshiyama T, Yamamoto M, Iranami H. Endothelium-dependent and -independent vasodilation of isolated rat aorta induced by caffeine. Am J Physiol 1995;269:H1679-H1684.
47. Montes FR, Cabrera M, Delgadillo A, Salgar C, Echeverri D. The role of potassium channels in the vasodilatory effect of caffeine in human internal mammary arteries. Vascul Pharmacol 2009;50:132-136.
48. Molloy JW, Calcagno CJ, Williams CD, Jones FJ, Torres DM, Harrison SA. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 2012;55:429-436.
49. Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, et al. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 2008;48:129-136.
50. Stavric B, Klassen R, Watkinson B, Karpinski K, Stapley R, Fried P. Variability in caffeine consumption from coffee and tea: possible significance for epidemiological studies. Food Chem Toxicol 1988;26:111-118.
51. Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience 2010;167:475-481.